Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (TA93) (replaced by CG131)
Irinotecan, oxaliplatin and raltitrexed for advanced colorectal cancer (review of TA33)
This guidance has been replaced by CG131 Colorectal cancer
This guidance updated and replaced NICE technology appraisal 33 (published in June 2001).
- Review decision - December 2008
- Review decision - December 2008: table of comments
- NICE extends its recommendations for the use of drugs for the treatment of advanced colorectal cancer
- TA93 Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (review): review proposal - October 2008
This page was last updated: 17 February 2014
Implementation tools and resources
- None available
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.